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Abstract 
Uveitis is a common association of juvenile idiopathic arthritis (JIA) that previously has been 
characterized by poor vision prognosis with limited options for effective treatment. Since 
corticosteroid treatment is not a preferred long-term option for most patients with this 
condition, systemic immunosuppressive therapy is frequently employed. The medical options 
for treatment of JIA-associated uveitis have recently expanded beyond conventional 
immunosuppressive drugs to the biologic agents. The biologic drugs that are most commonly 
employed for JIA-associated uveitis are the tumor necrosis factor alpha inhibitors. Other 
biologic agents that have been used to treat the disease include drugs that target cytokine 
receptors, lymphocyte antigens and lymphocyte co-stimulation signals. This Mini-Review 
highlights recent developments in the medical treatment of JIA-associated uveitis. 
 
Introduction 
Juvenile idiopathic arthritis is one of the commonest autoimmune diseases with an onset in 
childhood.  It is recognized as arthritis of unknown etiology with an onset before the age of 
16 and of at least 6 weeks duration, for which other potential medical causes have been ruled 
out.1 Anterior uveitis is an important association of JIA, with potentially sight-threatening 
course and complications, that occurs in 10-20% of all cases.2 Juvenile idiopathic arthritis-
associated uveitis was designated “Disease of the Year” in 2013 by the journal, Ocular 
Immunology and Inflammation, enhancing awareness of the disease and prompting review of 
the current state of understanding of the disease and its management. This Mini-Review 
focuses on recent developments in the medical treatment of JIA-associated uveitis. 
 
Disease Classification 
Seven mutually exclusive categories of JIA are defined by the International League of 
Associations for Rheumatology (ILAR):1 systemic arthritis; oligoarthritis (divided into 
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persistent and extended subcategories); polyarthritis (divided into rheumatoid factor negative 
and positive subcategories); psoriatic arthritis; enthesitis-related arthritis; and undifferentiated 
arthritis. The associated uveitis and the risk factors for development of ocular inflammation 
do not form part of the ILAR classification of JIA. 
 
Disease Manifestations 
As recognized by the ILAR classification, the systemic presentation and course of JIA is 
variable in terms of the number of joints involved and the extra-ocular manifestations.1 The 
subtypes also differ in age of onset, gender risk, ethnic predisposition, prognosis, as well as 
specific laboratory findings.3 Uveitis that occurs in association with JIA presents as chronic 
anterior uveitis – typically presenting with an asymptomatic “white” eye – or less commonly 
as HLA-B27-associated acute anterior uveitis in enthesitis-related arthritis.4 In the typical 
course, the uveitis lags behind the arthritis in onset; however some patients may present 
initially with uveitis and develop arthritis subsequently, usually within a period of months. 
Risk factors for the development of uveitis in JIA include early age of onset of disease, 
oligoarticular category, positive ANA and European ethnicity; uveitis also occurs more 
frequently in rheumatoid factor negative polyarthritis and psoriatic arthritis JIA subtypes.2  
 
Management of JIA-Associated Uveitis 
The management of JIA-associated uveitis involves both medical control of the inflammation 
and surgical approaches to its complications, particularly cataract. Intraocular surgery is 
outside the scope of this review, but readers are referred to an excellent recent review of 
cataract management in patients with JIA-related uveitis.5 Control of inflammation and the 
use of systemic immunosuppressive medications have been clearly associated with better 
visual acuity in patients with JIA-associated uveitis by the Systemic Immunosuppressive 
Therapy for Eye Disease (SITE) Cohort Study.6 In mild disease, treatment may be limited to 
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corticosteroid eye drops with or without a topical cycloplegic agent. When a topical 
corticosteroid is used no more than twice daily, the risk of drug-induced cataract formation is 
probably negligible.7 However, when such treatment is used more frequently, the risk of 
cataract and the difficulty in compliance often indicate the need for systemic treatment. 
 
Oral corticosteroid may be used to gain rapid control of active uveitis, but long-term 
treatment carries significant risk of morbidity in the pediatric population. Corticosteroid-
sparing systemic immunosuppressive drugs are effective in controlling a majority of cases of 
both joint and ocular disease in patients with JIA.4 The conventional immunosuppressive drug 
that is most commonly employed is methotrexate. Other anti-metabolites are alternatives to 
treat JIA-associated uveitis, including azathioprine, mycophenolate mofetil and leflunomide. 
Despite the absence of randomized controlled trials evaluating the efficacy of these agents in 
JIA uveitis, multiple case reports and case series have provided evidence of efficacy. 
Unfortunately, these drugs do not appear to change the course of disease; in one study 
conducted at the University Medical Center Utrecht, 69% of patients experienced a relapse of 
uveitis following cessation of methotrexate, which had controlled their disease for a median 
of 1.5 years.8 
 
In the past 5 years, the most exciting development in the medical treatment of JIA-associated 
uveitis has been application of biologic drugs in cases resistant to conventional systemic 
immunosuppressive therapy or in situations in which conventional agents cannot be used.   
Juvenile idiopathic arthritis-associated uveitis is currently not an approved condition for the 
use of any biologic drug internationally, and thus presently such treatment is prescribed “off-
label”. Biologic agents that have been used to treat JIA-associated uveitis include drugs that 
target: cytokines and cytokine receptors, i.e., tumor necrosis factor (TNF)-alpha, and the 
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interleukin (IL)-2 and IL-6 receptors; lymphocyte antigens, i.e., CD20; and lymphocyte co-
stimulation signals, i.e., CD80 and CD86. 
 
Tumor necrosis factor (TNF)-alpha inhibitors  
The TNF-alpha inhibitors represent the major class of biologic drug used today for JIA-
associated uveitis that is resistant to treatment with conventional immunosuppressive 
medications. The SITE Cohort Study described treatment success within 12 months in 75% of 
56 children with various forms of uveitis who were treated with TNF-alpha blockers; the 29 
patients with JIA-associated uveitis were significantly more likely to achieve quiescence 
irrespective of other systemic treatment. There are multiple TNF-alpha inhibitors in clinical 
use, including antibodies directed against the cytokine, i.e., infliximab and adalimumab, and 
decoy cytokine receptors, i.e., etanercept. In contrast to the antibodies, etanercept is generally 
considered to provide little therapeutic benefit for uveitis in patients with JIA. Unfortunately, 
however, recurrence of uveitis after discontinuation of TNF blockade appears to be relatively 
common.9 
 
The effectiveness of infliximab and adalimumab for JIA-associated uveitis has been 
compared in studies from clinical centers in Italy. Simonini and colleagues10 compared the 
clinical course for 16 children treated with infliximab with 12 children treated with 
adalimumab; a majority of these children had JIA-associated uveitis. There was a higher 
probability of remission over a 3-year period in the adalimumab-treated group. Zannin and 
co-workers11 used the National Italian Registry to show the same result. Interestingly, 
adalimumab appears to be more effective in inducing remission when used as primary 
biologic therapy.12 As highlighted by Mansour,13 other advantages of adalimumab may be 
superior tolerability, lower immunogenicity, and the option of home administration, being 
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delivered by subcutaneous injection in comparison to infliximab which requires intravenous 
infusion.   
 
The SYCAMORE trial is “the first randomized controlled trial …(to)… assess the clinical 
effectiveness, safety and cost effectiveness of …(a TNF-alpha inhibitor)… in combination 
with methotrexate for the treatment of JIA-associated uveitis”.14 This United Kingdom-based 
study is randomizing 154 patients with uveitis that is active despite treatment with 
methotrexate to receive additional treatment with adalimumab or placebo for a period of 18 
months. As a controlled clinical trial, results of this study are likely to be important in 
determining the place of TNF-alpha blockade in the treatment of JIA-associated uveitis.   
 
Daclizumab 
Daclizumab is a humanized monoclonal antibody that targets the alpha subunit of the IL-2 
receptor. Clinical investigators at the National Eye Institute conducted a small open-label 
prospective phase II study of 52-week treatment of daclizumab for JIA-associated uveitis 
approximately 5 years ago.15 They reported treatment success – determined as a 2-grade 
reduction in anterior chamber cell – in 4 of 6 patients. The investigators recommended larger 
randomized and masked trials. However, around the same time, production of daclizumab 
was discontinued, relating to decline in market demand as an immunosuppressive drug. 
Recently however, the drug has been under intensive study for the treatment of multiple 
sclerosis. Thus the recommended clinical trials in JIA-associated uveitis may now be 
possible. 
 
Tocilizumab  
Tocilizumab is a fully humanized monoclonal antibody that recognizes the IL-6 receptor. A 
handful of cases of recalcitrant JIA-associated uveitis, treated with tocilizumab, have been 
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described as part of two small case series collected at the University of Barcelona,16,17 that 
included patients with other uveitis subtypes. Thus, while it is too early to speculate about 
usefulness of the drug for this disease in particular, tocilizumab certainly is a potential 
addition to the biological armamentarium that is used to treat JIA-associated uveitis. 
 
Rituximab 
Extensive histopathological evaluation of the eye of a child with JIA-associated uveitis was 
recently undertaken by Parikh and colleagues,18 revealing many B cells and their progeny, 
plasma cells, within the eye. This research provides strong rationale for targeting the B cells 
in patients with the disease. Rituximab is a chimeric mouse-human monoclonal antibody that 
is directed against the CD20 surface marker of B cells and results in the death of these cells. 
Typically two infusions of drug are given two weeks apart. Two recent retrospective case 
series have included a total of 18 patients with JIA-associated uveitis who failed TNF 
blockade.19,20 These studies showed remission and/or drug sparing effects in over three 
quarters of patients, without occurrence of treatment-limiting complications. Re-treatment 
was effective when the intraocular inflammation recurred. 
 
Abatacept 
Cytotoxic T lymphocyte-associated antigen (CTLA)-4 prevents co-stimulation of T-cells by 
preventing CD28 binding to CD80 or CD86. Abatacept is a chimeric protein of 
immunoglobulin Fc and the extracellular portion of the CTLA-4 molecule. Abatacept has 
been found to control joint inflammation in JIA, in a large, randomized, double-blind, 
placebo-controlled withdrawal trial.21 In contrast, uncontrolled retrospective and prospective 
trials of abatacept for JIA-associated uveitis have been contradictory in terms of showing 
benefit for the intraocular inflammation.22,23  
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Use of Biologic Drugs 
Drug safety assessments of biologic drugs in the treatment of children with JIA-associated 
uveitis have not identified a high incidence of serious adverse events, but clearly the body of 
literature is limited, in terms of both number of patients and duration of follow-up. Allergic 
reactions may occur. As applies also to conventional systemic immunosuppressive drugs, the 
use of biologic drugs increases an individual’s risk of incidental infection. For the TNF-alpha 
inhibitors in particular, treatment carries the risk of reactivation of tuberculosis. Thus children 
must be thoroughly investigated to exclude existing infectious disease, including tuberculosis, 
and immunizations should be up-to-date ahead of initiating treatment. An unanswered 
question is whether there is an increased risk of malignancy in patients with JIA who are 
treated with biologic agents, and for younger patients the issue is particularly important; large, 
long-term studies will be necessary in order to address this question.24 Unrelated to drug 
safety concerns, a major challenge to the access to the biologic drugs for JIA-associated 
uveitis is their considerable cost.  
 
Outcomes of Disease 
The visual prognosis of JIA-associated uveitis has been considered guarded, with incidence of 
vision loss reported at 0.18 per eye-year in the SITE Cohort Study.6 However, biologic 
treatments may have a major impact on course of disease. The Multinational Interdisciplinary 
Working Group for Uveitis in Childhood25 has developed outcome measures specifically for 
JIA-associated uveitis, to aid in standardizing and categorizing response to treatment for 
future therapeutic clinical trials. Conformity of description and grading of ocular disease 
should allow better comparison between immunosuppressive drugs in relation to effectiveness 
and safety for the treatment of JIA-associated uveitis. 
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